Grifols (NASDAQ:GRFS - Get Free Report) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research note issued to investors on Monday.
Separately, JPMorgan Chase & Co. raised their price objective on shares of Grifols from $7.60 to $10.30 and gave the stock a "neutral" rating in a research note on Tuesday, June 17th.
View Our Latest Research Report on GRFS
Grifols Stock Performance
Shares of NASDAQ:GRFS traded up $0.25 during trading on Monday, reaching $9.64. The stock had a trading volume of 980,187 shares, compared to its average volume of 1,089,941. Grifols has a 52 week low of $6.19 and a 52 week high of $9.96. The firm has a market capitalization of $6.63 billion, a price-to-earnings ratio of 8.22, a P/E/G ratio of 0.32 and a beta of 0.55. The company has a quick ratio of 0.97, a current ratio of 2.60 and a debt-to-equity ratio of 1.13. The stock has a fifty day simple moving average of $8.37 and a two-hundred day simple moving average of $7.73.
Institutional Investors Weigh In On Grifols
Hedge funds and other institutional investors have recently modified their holdings of the stock. Versant Capital Management Inc acquired a new stake in shares of Grifols in the first quarter worth $28,000. Tower Research Capital LLC TRC grew its stake in shares of Grifols by 354.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company's stock worth $60,000 after acquiring an additional 6,335 shares during the last quarter. First Trust Advisors LP acquired a new stake in Grifols during the fourth quarter worth $75,000. Envestnet Portfolio Solutions Inc. acquired a new stake in Grifols during the fourth quarter worth $77,000. Finally, Ballentine Partners LLC acquired a new stake in Grifols during the first quarter worth $77,000.
Grifols Company Profile
(
Get Free Report)
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
Featured Articles
Before you consider Grifols, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grifols wasn't on the list.
While Grifols currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.